Semax
Semax is a synthetic peptide based on the ACTH (adrenocorticotropic hormone) fragment 4-10 with an added proline-glycine-proline tail for stability. Developed in Russia as a neuroprotective agent, it is approved there for stroke recovery, cognitive disorders, and optic nerve disease. Semax significantly increases BDNF and NGF expression in the brain, making it one of the most studied nootropic peptides for memory, learning, and neurological recovery.
FormBlends Peptide Context
Reviewed May 14, 2026The strongest way to read Semax peptide guide is to look for what changes the next step. For peptide therapy, that means checking whether the page is explaining evidence, eligibility, cost, safety, provider fit, or day-to-day use. The goal is not more words on the page. It is a clearer path from a broad question to a responsible medical conversation.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
Semax authority snapshot
Semax is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Early clinical or translational evidence
Regulatory reality
Not specifically addressed in 2023/2026 regulatory actions
Safety screen
Nasal irritation with intranasal administration, Mild headache, Rare hair loss reported at high doses should be reviewed in context.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for Semax?
Semax should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- Semax
- Category
- Cognitive
- Evidence
- Early clinical or translational evidence
- FDA status
- Not FDA approved
Step 1
Check evidence level
Semax is approved as a prescription medication in Russia and Ukraine for stroke recovery, cognitive enhancement, and neuroprotection. Russian clinical studies report benefits in stroke patients and ADHD. Like selank, the evidence comes primarily from Russian literature without Western replication.
Review evidenceStep 2
Screen safety context
Nasal irritation with intranasal administration, Mild headache, Rare hair loss reported at high doses should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessLast updated: April 3, 2026
Typical Dosage
200-600 mcg intranasally per day, divided into 2-3 doses. Some protocols use up to 1 mg daily for acute neurological conditions.
Administration
Intranasal spray, Subcutaneous injection
Typical Cost
$80-200/month
FDA Status
Not FDA Approved
Half-Life
Very short in plasma. Intranasal delivery provides rapid CNS absorption bypassing plasma metabolism.
Onset of Action
Cognitive effects reported within 30-60 minutes of intranasal dosing.
Bioavailability
Intranasal is the primary route. Some practitioners use subcutaneous injection.
About Semax
Semax is a synthetic heptapeptide based on ACTH(4-10), a fragment of adrenocorticotropic hormone. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro, with the Pro-Gly-Pro tail added for enzymatic stability (same stabilization strategy as selank). Molecular weight: 813.9 Da. CAS number: 80714-61-0.
Semax was developed at the Institute of Molecular Genetics in Moscow and has been approved as a prescription medication in Russia since 1994. Its approved indications include stroke recovery, cognitive disorders, peptic ulcers, and optic nerve atrophy. It's also prescribed off-label in Russia for ADHD and age-related cognitive decline.
The neuroprotective mechanism centers on neurotrophin upregulation. A 2009 study in Neurochemical Research (PMID: 19294502) showed that semax activates BDNF and NGF (nerve growth factor) expression in the brain after ischemic injury. These neurotrophins promote neuronal survival, growth, and repair. This isn't just theory: Russian clinical protocols use semax in acute stroke treatment alongside standard interventions.
The ADHD data is also noteworthy. A clinical study (PMID: 18833124) tested semax in children with ADHD and found improvements in attention, memory, and processing speed. This hasn't been replicated in FDA-standard trials, but the Russian clinical experience spans decades.
Typical dosing is 200-600 mcg intranasally 2-3 times daily. The nasal spray allows direct CNS delivery through olfactory nerve pathways. Onset of cognitive effects is typically 30-60 minutes. Higher doses (up to 1 mg intranasally) are used in the Russian stroke protocols.
Semax differs from selank in its primary effects: semax is primarily cognitive/neuroprotective while selank is primarily anxiolytic. They share the Pro-Gly-Pro stabilization tail and are sometimes combined by practitioners seeking both cognitive enhancement and anxiety reduction.
N-acetyl semax amidate is a modified version with enhanced blood-brain barrier penetration and longer duration of action. It costs more but some users report stronger effects per dose.
Store semax nasal spray refrigerated at 2-8C. Injectable semax should be reconstituted from lyophilized powder with bacteriostatic water and used within 21 days.
How Semax Works
Semax activates the melanocortin system and modulates the expression of neurotrophins, particularly BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor). It does not produce the adrenal stimulation typically associated with ACTH because it lacks the amino acid sequence responsible for cortisol release. Semax also modulates dopaminergic and serotonergic systems, enhances cerebral blood flow, and has demonstrated anti-inflammatory effects in neural tissue.
Receptor targets:
Benefits
- Significantly increases BDNF levels in the brain
- Enhances memory formation and learning capacity
- Provides neuroprotection against ischemic and oxidative damage
- Improves attention span and cognitive processing speed
- Supports stroke recovery and neural regeneration
- No cortisol stimulation despite being derived from ACTH
What Does the Research Say?
Semax is approved as a prescription medication in Russia and Ukraine for stroke recovery, cognitive enhancement, and neuroprotection. Russian clinical studies report benefits in stroke patients and ADHD. Like selank, the evidence comes primarily from Russian literature without Western replication.
Semax, an ACTH(4-10) analogue with nootropic properties, activates neurotrophin system during recovery from brain ischemia
Neurochemical Research, 2009 · DOI · PubMed
Semax activated BDNF and NGF expression in rat brains after ischemic stroke, supporting its neuroprotective mechanism
The effects of semax on cognitive function in children with ADHD
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 · PubMed
Clinical study in children with ADHD showed semax improved attention, memory, and cognitive processing speed
PubMed evidence trail
Research sources used to frame this page
For Semax, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Potential Side Effects
- Nasal irritation with intranasal administration
- Mild headache
- Rare hair loss reported at high doses
- Irritability in sensitive individuals
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Stimulant medications (methylphenidate, amphetamines) | Both enhance dopaminergic signaling. Combining could amplify stimulant effects. Russian ADHD studies used semax as monotherapy, not alongside stimulants. | moderate |
Who Is Semax For?
Women
No sex-specific contraindications in published data. Used similarly in men and women.
Adults Over 50
Potentially relevant for age-related cognitive decline. Neuroprotective properties may help preserve cognitive function, but no long-term aging studies in humans.
Athletes
Not on WADA's prohibited list. Sometimes used for focus and mental clarity during competition.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Not specifically addressed in 2023/2026 regulatory actions
Not FDA-approved in the US but approved as a prescription medication in Russia. Available through US compounding pharmacies.
Last verified: 2026-04-06
Stacking Options
Semax is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get Semax from FormBlends
Pharmaceutical-grade semax with free physician consultation.
View Product DetailsFind a Semax Clinic Near You
Browse peptide therapy clinics in your area that offer semax treatments.
Find Peptide Clinics